Vitrafy Life Sciences Limited (ASX: VFY)

Vitrafy Life Sciences Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Operating Revenue	0.04	0.04	0.03	-
Other Revenue	-	-	2.02	1.83
Revenue	0.04	0.04	2.06	1.83
Revenue Growth (YoY)	-	-98.19%	12.63%	-
Cost of Revenue	-	-	0.03	0.01
Gross Profit	0.04	0.04	2.03	1.82
Selling, General & Admin	2.83	2.83	4.35	3.78
Research & Development	4.25	4.25	1.69	1.28
Other Operating Expenses	3.66	3.66	3.12	1.37
Operating Expenses	10.73	10.73	9.17	6.43
Operating Income	-10.69	-10.69	-7.14	-4.61
Interest Expense	-10.43	-10.43	-4.99	-2.73
Interest & Investment Income	0.03	0.03	-	-
Currency Exchange Gain (Loss)	0.02	0.02	-0	-
Other Non Operating Income (Expenses)	10.64	10.64	4.32	-0.32
Pretax Income	-10.43	-10.43	-7.81	-7.66
Net Income	-10.43	-10.43	-7.81	-7.66
Net Income to Common	-10.43	-10.43	-7.81	-7.66
Shares Outstanding (Basic)	3	3	3	3
Shares Outstanding (Diluted)	3	3	3	3
Shares Change (YoY)	-	4.02%	0.73%	-
EPS (Basic)	-3.40	-3.40	-2.65	-2.62
EPS (Diluted)	-3.40	-3.40	-2.65	-2.62
Free Cash Flow	-6.8	-6.8	-5.05	-6.36
Free Cash Flow Per Share	-2.22	-2.22	-1.71	-2.17
Gross Margin	100.00%	100.00%	98.62%	99.68%
Operating Margin	-28767.86%	-28767.86%	-347.14%	-252.69%
Profit Margin	-28051.11%	-28051.11%	-379.91%	-419.56%
Free Cash Flow Margin	-18308.88%	-18308.88%	-245.44%	-348.32%
EBITDA	-10.58	-10.58	-6.98	-4.48
EBITDA Margin	-	-	-	-245.56%
D&A For EBITDA	0.11	0.11	0.16	0.13
EBIT	-10.69	-10.69	-7.14	-4.61
EBIT Margin	-	-	-	-252.69%

Source: S&P Capital IQ. Standard template. Financial Sources.